Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early prediction of adalimumab steady-state levels with InsightRx
NL-OMON49110Active, not recruiting
- Sponsor
- Máxima Medisch Centrum
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of adalimumab in Crohn's disease, autoimmune colitis, rheumatoid arthritis (RA) and 2 more, sponsored by Máxima Medisch Centrum. Primary endpoint: Accuracy of adalimumab steady-state level prediction. Started Mar 2019; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's diseaseautoimmune colitisrheumatoid arthritis (RA)psoriatic arthritis (PsA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on NL-OMON49110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49110.